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Aortitis and bilateral ureteral obstruction after
endovascular repair of abdominal aortic aneurysm
P. Jetty, MD, and G. G. Barber, MD, Ottawa, Ontario, Canada
A bifurcated stent graft was used to treat an asymptomatic 5.4-cm abdominal aortic aneurysm in a 76-year-old man. No
endoleaks or inflammatory changes were seen on the 1-month follow-up computed tomography scan. Five months later
the patient had acute renal failure and ureteral obstruction secondary to significant inflammatory changes in the aneurysm
wall. After bilateral ureteral stenting, conservative treatment included tamoxifen and steroid therapy. The patient remains
symptom-free, and at 2-year follow-up a computed tomography scan demonstrated decreased inflammation and
shrinkage of the excluded abdominal aortic aneurysm. (J Vasc Surg 2004;39:1344-7.)The role of endovascular aneurysm repair (EVAR) is
becoming better defined as more reports emerge with
respect to long-term outcomes. Its use in the treatment of
inflammatory aneurysms is controversial. Whether the in-
flammatory process is abated or exacerbated by the inser-
tion of a stent graft is not entirely known. We report a case
in which significant aortitis developed, causing acute renal
failure, after insertion of a stent graft.
CASE REPORT
A 76-year-old man was seen by his general practitioner, ini-
tially with calf claudication. Routine investigation revealed a
5.4-cm abdominal aortic aneurysm (AAA), which was completely
asymptomatic. Medical history included hypertension. The patient
had smoked half a pack of cigarettes per day, but quit 1 month
previously. His mother had had an AAA, and died at age 92 years.
Physical examination revealed a nontender AAA. The complete
blood cell count was normal, and creatinine concentration (Cr)
was 109 mmol/L (1.2 mg/dL). A computed tomography (CT)
scan demonstrated a 5.4-cm infrarenal AAA (Fig 1). There was no
evidence of any inflammatory changes in the retroperitoneum at
this time. An angiogram revealed suitable anatomy for EVAR (Fig
2).
Four months after presentation, the patient underwent EVAR
with an AneuRx device (Medtronic) under general anesthesia.
Through bilateral groin dissections, a modular graft was deployed
approximately 2 mm below the lowest renal artery. The aortic
diameter at the proximal fixation point was 23 mm. The main body
of the graft was 28 mm proximally and 16 mm distally, with a total
covered length of 165 mm, landing the graft in the right common
iliac artery. After the left limb of the graft was deployed, an
extension into the external iliac artery (16-mm  8.5-cm length)
on the left side was used to seal a type I endoleak. There was no
evidence of any endoleak at the end of the procedure. Systemic
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doi:10.1016/j.jvs.2004.02.0301344heparinization was used, and was not reversed. The patient toler-
ated the procedure well, and was discharged from the hospital 3
days later.
The 1-month follow-up CT scan revealed an AAA with no
evidence of endoleak, and unchanged in maximum diameter (5.4
cm). The aneurysm wall was free of any inflammatory changes (Fig
3). At a 2-month postoperative clinic visit the patient complained
of some fatigue, but was otherwise well, and the AAA was non-
tender.
Five months postoperatively, the patient had anuria, Cr of 658
mmol/L (7.5 mg/dL), and erythrocyte sedimentation rate (ESR)
of 40 mm/hr (normal, 0-6 mm/hr). A CT scan revealed bilateral
hydronephrosis and hydroureter, with significant inflammatory
changes in the wall of the excluded aneurysm measuring 1.5-cm
thick. The inflammation involved mainly the anterior and lateral
walls of the aneurysm, extending from the renal arteries down to
the bifurcation of the aorta, compromising the ureters and the
inferior vena cava. The rest of the retroperitoneum was relatively
free of inflammation or fibrosis. There was no evidence of endoleak
(Fig 4). The diagnosis of aortitis was made, although retroperito-
neal fibrosis could not be entirely excluded. The patient underwent
dialysis the next day, as well as bilateral ureteral stenting. Therapy
was started with tamoxifen 10 mg orally twice a day and prednisone
60 mg orally once a day.
Follow-up 1 month later revealed a significant improvement in
renal function (Cr 142 mmol/L [1.6 mg/dL]), significant im-
provement of the inflammation, and detectable shrinkage of the
AAA on CT scans. Repeat follow-up 5 months later revealed a
decrease in ESR (8 mm/hr), and even more improvement on CT
scans (Fig 5). C-reactive protein concentration, increased to 19.4
mg/L initially, was now 7.6 mg/L (normal, 8.0 mg/L). The
ureteral stents were eventually removed at 9 and 12 months,
respectively, after insertion. Prednisone therapy was also stopped,
after approximately 1 year, because the patient was experiencing
profound weakness and fatigue, and changes in his appearance.
Tamoxifen therapy was continued. A CT scan 24 months after
onset of the inflammation revealed the presence of mild inflamma-
tion, with maximum diameter of 5.2 cm (Fig 6). The patient
remains asymptomatic, with good renal function (Cr 140 mmol
[1.6 mg/dl]) and no reinsertion of ureteral stents. He is still
receiving tamoxifen therapy.
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Complications of EVAR are well described, and include
migration and endoleak, late rupture, graft thrombosis,
graft infection, and rarely aortoduodenal fistula. To our
knowledge, there has been only one other case report of a
complication similar to the one in our patient.1 That report
presented a 59-year-old man who underwent EVAR to
treat a noninflammatory AAA, with a Talent bifurcated
device (Medtronic). At 1 year there was evidence of new
inflammation in the aneurysm wall on the follow-up CT
scan. Seventeen months postoperatively the patient had
flank pain, with normal Cr. Ultrasonography revealed a
dilated ureter secondary to an inflammatory process in the
wall of the aneurysm, which was confirmed on a CT scan.
Fig 1. Initial preoperative computed tomography scan reveals a
normal 5.4-cm infrarenal AAA.
Fig 2. Preoperative angiogram. The patient eventually underwent nephrectomy, and ta-
moxifen therapy was started when an interval CT scan
revealed worsening of the inflammation.
Other articles have described onset of inflammation
after stent-graft insertion in animal models,2,3 and also in
human beings.4,5 Vallabhaneni et al6 described their expe-
rience with 10 patients; low-grade aortitis developed in
approximately 18% of these patients. This was purely a
radiologic finding, and was not necessarily clinically signif-
icant. They also described their experience with EVAR of
preoperatively known inflammatory AAAs. They noted that
all of their patients (n  6) had either persistence or
worsening of the inflammation after insertion of the stent
graft, possibly representing a relative contraindication of
the use of EVAR in inflammatory AAAs. This was sup-
ported by another case report.6 However, there are also
data that describe successful treatment of inflammatory
Fig 3. Postoperative computed tomography scan at 1-month
follow-up reveals an excluded AAA without evidence of endoleak.
Fig 4. Computed tomography scan obtained at admission with
acute renal failure at 5 months postoperatively reveals a 1.5-cm
inflamed and thickened aneurysm wall.
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stent graft abated the inflammatory process in these cases.
Our case is unique in that the inflammatory process
followed EVAR, and was aggressive enough to cause bilat-
eral ureteral obstruction and acute renal failure. Theories of
an immune modulated reaction to the graft material, and
spontaneous retroperitoneal fibrosis were entertained, but
the exact mechanism remains unknown. Inasmuch as there
was no radiologic evidence of endoleak or aneurysm expan-
sion, it was believed safe to manage this patient expectantly.
The use of prednisone in inflammatory AAAs has been
shown to induce resolution of symptoms and ureteral ob-
struction, and decrease in ESR.11 However, steroids also
have well-described detrimental effects on wound healing
Fig 5. Computed tomography scan obtained 5 months after
treatment of acute renal failure with bilateral ureteral stents, and
prednisone and tamoxifen. Note almost complete resolution of the
inflammatory process in the wall of the aneurysm.
Fig 6. Computed tomography scan obtained at 2-year follow-up.
Note evidence of mild recurrent inflammation in the wall of the
aneurysm. There is no evidence of endoleak, and the diameter of
the AAA is 5.2 cm. The patient was receiving only tamoxifen
therapy at this time.and immune response, which need to be considered when
planning a procedure such as AAA repair.
The distinction between inflammatory AAA and retro-
peritoneal fibrosis is not entirely clear, because the patho-
genesis of both entities is poorly understood. Retroperito-
neal fibrosis is characterized by development of a fibrotic
mass centered around the sacral promontory enveloping
the aorta and the ureters, which is similar to that seen in
inflammatory AAA.12 Retroperitoneal fibrosis can also re-
sult from use of certain medications, such as methysergide,
-adrenergic blockers, methyldopa, amphetamines, and
cocaine, none of which were used by our patient.
The rationale for use of tamoxifen in our patient is
based on its successful use in patients with retroperitoneal
fibrosis. Clarke et al13 introduced the concept of using
tamoxifen, a nonsteroidal antiestrogenic compound, for
treatment of retroperitoneal fibrosis, because it shares a
similar invasive fibroblastic proliferation seen with desmoid
tumors, which were known to respond well to tamoxifen.
Since that study there have been several case reports with
good results with use of tamoxifen in the treatment of
retroperitoneal fibrosis in adults.14-16
The combination of both prednisone and tamoxifen
has led to enough resolution of the inflammatory process to
enable uninhibited urinary excretion in our patient. At
27-month follow-up he remained well, with no evidence of
endoleak or expansion, and Cr of 140 mmol/L.
Short and long-term complications of EVAR are be-
coming more apparent, thus better defining its role in the
treatment of AAA. However, until the pathophysiology of
inflammatory AAA is better understood, the role of EVAR
in their treatment remains controversial.
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